Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Shagera QA, Karfis I, Sideris S, Guiot T, et al. Clin Nucl Med 2023 Jun 29. doi: 10.1097/RLU.0000000000004763.

Read + Share

Amedeo Smart

Independent Medical Education

Shagera QA, Karfis I, Sideris S, Guiot T, et al. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Clin Nucl Med 2023 Jun 29. doi: 10.1097/RLU.0000000000004763.
PMID: 37385221